Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-189-196
A. Baranovsky, N. A. Kruglova, E. Grigoreva
The results of a study of the clinical efficacy of dietary treatment in patients with non-alcoholic liver disease (NAFLD) with the additional inclusion of a new specialized nutritional functional dietary product “A mixture of essential nutrients multicomponent dry” (SENMS) in the product content of the standard D3 diet are presented. 75 patients with NAFLD were examined (39 - study group, 36 - control group). The patients in the study group received 6 g of SENMS daily for 2 weeks, consisting of 6 ingredients that are sources of biologically active substances: inulin, green tea extract, dry red wine extract, L-carnitine, grape seed extract, coenzyme Q10. As a result of the conducted study, it was proved that the SEMS in patients with NAFLD contributed to a faster decrease in the severity of hepatic parenchymal inflammation compared with the control, improved cholesterol metabolism, lipid peroxidation, and quality of life indicators of patients. In conclusion, the expediency of using a new specialized functional dietary food product “A mixture of essential nutrients multicomponent dry” in dietary treatment programs for patients with NAFLD was noted.
{"title":"Functional nutrition option patients with non-alcoholic fatty liver disease","authors":"A. Baranovsky, N. A. Kruglova, E. Grigoreva","doi":"10.31146/1682-8658-ecg-218-10-189-196","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-189-196","url":null,"abstract":"The results of a study of the clinical efficacy of dietary treatment in patients with non-alcoholic liver disease (NAFLD) with the additional inclusion of a new specialized nutritional functional dietary product “A mixture of essential nutrients multicomponent dry” (SENMS) in the product content of the standard D3 diet are presented. 75 patients with NAFLD were examined (39 - study group, 36 - control group). The patients in the study group received 6 g of SENMS daily for 2 weeks, consisting of 6 ingredients that are sources of biologically active substances: inulin, green tea extract, dry red wine extract, L-carnitine, grape seed extract, coenzyme Q10. As a result of the conducted study, it was proved that the SEMS in patients with NAFLD contributed to a faster decrease in the severity of hepatic parenchymal inflammation compared with the control, improved cholesterol metabolism, lipid peroxidation, and quality of life indicators of patients. In conclusion, the expediency of using a new specialized functional dietary food product “A mixture of essential nutrients multicomponent dry” in dietary treatment programs for patients with NAFLD was noted.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"19 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-160-167
I. Kurbatova, A. Vasileva, L. Topchieva, O. Dudanova, A. A. Shopovskaya
Purpose: Comparative analysis of the expression level of long non-coding RNAs MALAT1, GAS5, DANCR, TUG1 in peripheral blood leukocytes (PBL) of healthy people and patients with NAFLD (liver steatosis, NASH of varying activity, liver cirrhosis). Materials and methods: We examined 106 patients diagnosed with NAFLD for the first time: 31 patients with liver steatosis (LS), 64 patients with weak (WA), moderate (MA) and high (HA) NASH activity and 11 patients at the stage of liver cirrhosis (LC). The control group consisted of 30 healthy donors. The mRNA level of the TUG1, DANCR, MALAT1, GAS5 genes in PBL was determined by RT-PCR. Results: A higher level of expression of the TUG1 gene was registered in the PBL of patients with NASH-WA compared to LS, and a tendency was revealed to increase the level of TUG1 mRNA in the PBL with increasing NASH activity, which indicates the possibility of using the level of TUG1 expression in the PBL as a minimally invasive diagnostic (to distinguish between LS and NASH-WA) and a prognostic marker (with the progression of NAFLD). Analysis of the expression level of lncRNA MALAT1 showed no significant differences between all studied groups. Results were obtained indicating complex dynamics of the GAS5 expression level: the level of transcripts increases during the formation of liver steatosis and then decreases during the transition to NASH. It was shown that the level of DANCR expression in the PBL of patients with NASH-WA is significantly lower than in patients with liver steatosis and NASH-MA. Conclusion: New data were obtained on the expression level of the MALAT1, GAS5, DANCR, TUG1 lncRNAs in the PBL of patients with NAFLD, indicating the possibility of using the level of TUG1 expression in the PBL as a minimally invasive diagnostic and prognostic marker in NAFLD. It has also been shown that the level of DANCR mRNA in PBL may have some diagnostic value in distinguishing between LS and NASH-WA.
{"title":"Expression level of long non-coding RNA MALAT1, GAS5, DANCR and TUG1 in peripheral blood leukocytes of patients with non-alcoholic fatty liver disease","authors":"I. Kurbatova, A. Vasileva, L. Topchieva, O. Dudanova, A. A. Shopovskaya","doi":"10.31146/1682-8658-ecg-218-10-160-167","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-160-167","url":null,"abstract":"Purpose: Comparative analysis of the expression level of long non-coding RNAs MALAT1, GAS5, DANCR, TUG1 in peripheral blood leukocytes (PBL) of healthy people and patients with NAFLD (liver steatosis, NASH of varying activity, liver cirrhosis). Materials and methods: We examined 106 patients diagnosed with NAFLD for the first time: 31 patients with liver steatosis (LS), 64 patients with weak (WA), moderate (MA) and high (HA) NASH activity and 11 patients at the stage of liver cirrhosis (LC). The control group consisted of 30 healthy donors. The mRNA level of the TUG1, DANCR, MALAT1, GAS5 genes in PBL was determined by RT-PCR. Results: A higher level of expression of the TUG1 gene was registered in the PBL of patients with NASH-WA compared to LS, and a tendency was revealed to increase the level of TUG1 mRNA in the PBL with increasing NASH activity, which indicates the possibility of using the level of TUG1 expression in the PBL as a minimally invasive diagnostic (to distinguish between LS and NASH-WA) and a prognostic marker (with the progression of NAFLD). Analysis of the expression level of lncRNA MALAT1 showed no significant differences between all studied groups. Results were obtained indicating complex dynamics of the GAS5 expression level: the level of transcripts increases during the formation of liver steatosis and then decreases during the transition to NASH. It was shown that the level of DANCR expression in the PBL of patients with NASH-WA is significantly lower than in patients with liver steatosis and NASH-MA. Conclusion: New data were obtained on the expression level of the MALAT1, GAS5, DANCR, TUG1 lncRNAs in the PBL of patients with NAFLD, indicating the possibility of using the level of TUG1 expression in the PBL as a minimally invasive diagnostic and prognostic marker in NAFLD. It has also been shown that the level of DANCR mRNA in PBL may have some diagnostic value in distinguishing between LS and NASH-WA.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"13 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140241180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-202-215
A. Kislenko, A. Razumovsky, V. V. Kholostova, Z. B. Mitupov, A. Zadvernyuk, G. Y. Chumakova
Chronic pancreatitis in children is a continuous or recurrent disease characterized by irreversible inflammatory and destructive changes in the pancreas (PG), progressive fibrosis, accompanied by a gradual decrease in its exocrine and endocrine functions. In recent decades, there has been a significant increase in patients with CP; the incidence in children is estimated at 2 cases per 100,000 people. According to the literature, pancreatic cancer in the outcome of chronic pancreatitis in childhood is 6.2%. Mortality rates for CP vary in different studies: 15-20% of children with CP die from complications and secondary disorders. The purpose of the study is to study current problems and determine the prospects for the treatment of chronic pancreatitis in children based on a review of modern literature. Materials and methods. As part of the preparation, a systematic review of the world and domestic literature on the surgical treatment of chronic pancreatitis in children was carried out. Results. A literature search confirmed the lack of consensus regarding the surgical treatment of CP in children. The small number of observations does not allow us to analyze the long-term results of surgical treatment of children with CP. Patients with hereditary pancreatitis pose a particular challenge; treatment algorithms for this group of patients are not described in the literature. Also in the literature there are isolated descriptions of complications with CP in children; there are no reliable results of the effectiveness of surgical intervention for endocrine and exocrine insufficiency in children. It is necessary to conduct scientific and practical research to develop indications for surgical treatment of children with CP and to verify specific complications.
{"title":"Surgical treatment of chronic pancreatitis in children","authors":"A. Kislenko, A. Razumovsky, V. V. Kholostova, Z. B. Mitupov, A. Zadvernyuk, G. Y. Chumakova","doi":"10.31146/1682-8658-ecg-218-10-202-215","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-202-215","url":null,"abstract":"Chronic pancreatitis in children is a continuous or recurrent disease characterized by irreversible inflammatory and destructive changes in the pancreas (PG), progressive fibrosis, accompanied by a gradual decrease in its exocrine and endocrine functions. In recent decades, there has been a significant increase in patients with CP; the incidence in children is estimated at 2 cases per 100,000 people. According to the literature, pancreatic cancer in the outcome of chronic pancreatitis in childhood is 6.2%. Mortality rates for CP vary in different studies: 15-20% of children with CP die from complications and secondary disorders. The purpose of the study is to study current problems and determine the prospects for the treatment of chronic pancreatitis in children based on a review of modern literature. Materials and methods. As part of the preparation, a systematic review of the world and domestic literature on the surgical treatment of chronic pancreatitis in children was carried out. Results. A literature search confirmed the lack of consensus regarding the surgical treatment of CP in children. The small number of observations does not allow us to analyze the long-term results of surgical treatment of children with CP. Patients with hereditary pancreatitis pose a particular challenge; treatment algorithms for this group of patients are not described in the literature. Also in the literature there are isolated descriptions of complications with CP in children; there are no reliable results of the effectiveness of surgical intervention for endocrine and exocrine insufficiency in children. It is necessary to conduct scientific and practical research to develop indications for surgical treatment of children with CP and to verify specific complications.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"20 52","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-234-238
S. Kutia, N. Nikolaeva, A. Yermoshin
The article presents a translation of the chapters of the work “Onomatologia anatomica” (1880) by the Austrian anatomist Josef Hyrtl, devoted to terminology in anatomy of peritoneum and its derivatives - № 135 (“Epiploon”), № 233 (“Mesenterium und Mesaraion”), № 251 (“Omentum”), № 274 (“Peritoneum oder Peritonaeum”).
文章介绍了奥地利解剖学家约瑟夫-希特尔（Josef Hyrtl）的著作《解剖学》（1880 年）中有关腹膜及其衍生物解剖学术语的章节译文--№135（"Epiploon"）、№233（"Mesenterium und Mesaraion"）、№251（"Omentum"）、№274（"Peritoneum oder Peritonaeum"）。
{"title":"Josef Hyrtl on the origin of Latin name “peritoneum” and its derivatives","authors":"S. Kutia, N. Nikolaeva, A. Yermoshin","doi":"10.31146/1682-8658-ecg-218-10-234-238","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-234-238","url":null,"abstract":"The article presents a translation of the chapters of the work “Onomatologia anatomica” (1880) by the Austrian anatomist Josef Hyrtl, devoted to terminology in anatomy of peritoneum and its derivatives - № 135 (“Epiploon”), № 233 (“Mesenterium und Mesaraion”), № 251 (“Omentum”), № 274 (“Peritoneum oder Peritonaeum”).","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"15 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-182-188
A. I. Pal'tsev
The article shows that chronic opisthorchiasis is a systemic and comorbid disease caused by the trematode Opistorhis felineus when consuming fish of the carp family that is not sufficiently salted or heat-treated. The systemic nature of the disease lies in the fact that with opisthorchiasis, the organs of the helminth’s permanent habitat are affected; organs located on the paths of its migration, as well as intact organs and systems. The described syndromes and symptoms indicate the comorbidity of the pathology. The author describes a three-stage system for the treatment of chronic opisthorchiasis, including gentle specific therapy.
{"title":"Chronic opisthorchiasis - as a systemic pathology and issues of comorbidity. Clinic, diagnosis, treatment","authors":"A. I. Pal'tsev","doi":"10.31146/1682-8658-ecg-218-10-182-188","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-182-188","url":null,"abstract":"The article shows that chronic opisthorchiasis is a systemic and comorbid disease caused by the trematode Opistorhis felineus when consuming fish of the carp family that is not sufficiently salted or heat-treated. The systemic nature of the disease lies in the fact that with opisthorchiasis, the organs of the helminth’s permanent habitat are affected; organs located on the paths of its migration, as well as intact organs and systems. The described syndromes and symptoms indicate the comorbidity of the pathology. The author describes a three-stage system for the treatment of chronic opisthorchiasis, including gentle specific therapy.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"123 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140237970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-175-181
A. L. Alyavi, G. N. Sobirova, A. O. Abdullaev, D. A. Shadmanova
The purpose of the study is to evaluate the status and capabilities of modern types of diagnostics of non-alcoholic fatty liver disease as part of a meta-analysis of scientific data. Materials and methods. The literature search was carried out in electronic databases Cochrane Library, PubMed.gov, Elsevier.com, Google Scholar. The analysis of the data obtained was focused on works published between 2010 and 2023 (the bias in the form of later studies was used in isolated cases when it came to fundamental scientometric data). Results. After reviewing 693 scientific papers for duplication and inconsistency, 38 sources were selected. Conclusions. The analysis of scientific data revealed that despite the understanding of the pathogenetic causes of non-alcoholic fatty liver disease and the complexity of this disease, liver biopsy still remains the gold standard for assessing liver health. In this regard, there is a need to introduce accessible non-imaging tools and accurate biomarkers, with the help of which it will be possible not only to make an adequate diagnosis, but also to analyze new treatments for NAFLD in clinical trials.
{"title":"Ways to overcome difficulties in diagnosing non-alcoholic fatty liver disease","authors":"A. L. Alyavi, G. N. Sobirova, A. O. Abdullaev, D. A. Shadmanova","doi":"10.31146/1682-8658-ecg-218-10-175-181","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-175-181","url":null,"abstract":"The purpose of the study is to evaluate the status and capabilities of modern types of diagnostics of non-alcoholic fatty liver disease as part of a meta-analysis of scientific data. Materials and methods. The literature search was carried out in electronic databases Cochrane Library, PubMed.gov, Elsevier.com, Google Scholar. The analysis of the data obtained was focused on works published between 2010 and 2023 (the bias in the form of later studies was used in isolated cases when it came to fundamental scientometric data). Results. After reviewing 693 scientific papers for duplication and inconsistency, 38 sources were selected. Conclusions. The analysis of scientific data revealed that despite the understanding of the pathogenetic causes of non-alcoholic fatty liver disease and the complexity of this disease, liver biopsy still remains the gold standard for assessing liver health. In this regard, there is a need to introduce accessible non-imaging tools and accurate biomarkers, with the help of which it will be possible not only to make an adequate diagnosis, but also to analyze new treatments for NAFLD in clinical trials.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"124 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140237699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-95-103
E. Shrayner, A. I. Khavkin, K. Nikolaychuk, M. F. Novikova, A. S. Veremenko, I. D. Levchenko, E. E. Vergunova, A. S. Tumas, P. Y. Platonova, D. R. Shaimardanova, I. A. Pak, E. Pokushalov
The article highlights the pharmacological activity of berberine, as well as its place in the treatment of the current epidemic - metabolic syndrome. The review examines the molecular mechanisms that allows achieving anti-inflammatory, antimicrobial and antioxidant effects in detail. Berberine’s pharmacological profile makes it possible to have a positive effect on the pathway of obesity, non-alcoholic fatty liver disease, dyslipoproteinemia, the intestinal microbiome and insulin resistance. In addition, the article reviews the main pharmacokinetic parameters and side effects of chemically unmodified berberine.
{"title":"The place of berberine in the treatment of metabolic syndrome","authors":"E. Shrayner, A. I. Khavkin, K. Nikolaychuk, M. F. Novikova, A. S. Veremenko, I. D. Levchenko, E. E. Vergunova, A. S. Tumas, P. Y. Platonova, D. R. Shaimardanova, I. A. Pak, E. Pokushalov","doi":"10.31146/1682-8658-ecg-218-10-95-103","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-95-103","url":null,"abstract":"The article highlights the pharmacological activity of berberine, as well as its place in the treatment of the current epidemic - metabolic syndrome. The review examines the molecular mechanisms that allows achieving anti-inflammatory, antimicrobial and antioxidant effects in detail. Berberine’s pharmacological profile makes it possible to have a positive effect on the pathway of obesity, non-alcoholic fatty liver disease, dyslipoproteinemia, the intestinal microbiome and insulin resistance. In addition, the article reviews the main pharmacokinetic parameters and side effects of chemically unmodified berberine.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140239260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-48-56
M. M. Fedorin, M. Livzan, O. Gaus
The aim of the study: to study the characteristics of the course of irritable bowel syndrome (IBS), associated with overweight and obesity, to optimize the management of this group of patients. Material and methods. An open-label cross-sectional study was performed including 175 participants aged 18 to 44 years (mean age 30.06 ± 6.15 years). Group 1 included 100 patients with IBS aged 18 to 44 years (mean age 30.63 ± 6.37 years, BMI 25.88 ± 6.28 kg/m2). In group 1, subgroup 1A included 50 people with IBS associated with overweight or obesity. Subgroup 1B included 50 IBS patients with normal weight. Group 2 included 75 people who did not suffer from IBS, aged from 19 to 43 years (mean age 29.31 ± 5.81 years, BMI 27.80 ± 6.20 kg/m2). Subgroup 2A included 50 participants who did not suffer from IBS and were overweight or obese. Subgroup 2B included 25 apparently healthy participants. The presence and severity of IBS symptoms were assessed using a 10-point scale. The severity of gastrointestinal symptoms, the presence of anxiety and depression, the level of specific anxiety, quality of life and eating habits were assessed using verified questionnaires. All participants underwent a study of the levels of leptin and adiponectin in the blood serum and zonulin in the feces. Results. The characteristic clinical stigmas in patients suffering from IBS associated with overweight and obesity are described: IBS with a predominance of constipation, severe course of the disease, high incidence of signs of depressive and anxiety disorders, special eating habits characterized by the predominance of flour, sweet, fatty and salty foods in the diet food, severe disturbances in the permeability of the intestinal epithelial barrier. High concentrations of leptin and low levels of adiponectin in the blood serum of such patients may play a significant role in the formation of IBS symptoms. Conclusion. The results obtained open up opportunities for research into the pathogenetic mechanisms of the formation of IBS in people with overweight and obesity, as well as modification of existing treatment regimens for patients with IBS.
{"title":"Features of the course of irritable bowel syndrome in overweight and obese people","authors":"M. M. Fedorin, M. Livzan, O. Gaus","doi":"10.31146/1682-8658-ecg-218-10-48-56","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-48-56","url":null,"abstract":"The aim of the study: to study the characteristics of the course of irritable bowel syndrome (IBS), associated with overweight and obesity, to optimize the management of this group of patients. Material and methods. An open-label cross-sectional study was performed including 175 participants aged 18 to 44 years (mean age 30.06 ± 6.15 years). Group 1 included 100 patients with IBS aged 18 to 44 years (mean age 30.63 ± 6.37 years, BMI 25.88 ± 6.28 kg/m2). In group 1, subgroup 1A included 50 people with IBS associated with overweight or obesity. Subgroup 1B included 50 IBS patients with normal weight. Group 2 included 75 people who did not suffer from IBS, aged from 19 to 43 years (mean age 29.31 ± 5.81 years, BMI 27.80 ± 6.20 kg/m2). Subgroup 2A included 50 participants who did not suffer from IBS and were overweight or obese. Subgroup 2B included 25 apparently healthy participants. The presence and severity of IBS symptoms were assessed using a 10-point scale. The severity of gastrointestinal symptoms, the presence of anxiety and depression, the level of specific anxiety, quality of life and eating habits were assessed using verified questionnaires. All participants underwent a study of the levels of leptin and adiponectin in the blood serum and zonulin in the feces. Results. The characteristic clinical stigmas in patients suffering from IBS associated with overweight and obesity are described: IBS with a predominance of constipation, severe course of the disease, high incidence of signs of depressive and anxiety disorders, special eating habits characterized by the predominance of flour, sweet, fatty and salty foods in the diet food, severe disturbances in the permeability of the intestinal epithelial barrier. High concentrations of leptin and low levels of adiponectin in the blood serum of such patients may play a significant role in the formation of IBS symptoms. Conclusion. The results obtained open up opportunities for research into the pathogenetic mechanisms of the formation of IBS in people with overweight and obesity, as well as modification of existing treatment regimens for patients with IBS.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"22 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-120-124
R. K. Alfardan, W. N. Alismaeel
Background: Pancreatic cancer is a relatively uncommon type of cancer, although it is often very aggressive and highly metastases to other parts of the body. Investigating a potential gene marker or gene targeted therapy can improve the patient’s early prognosis and/or treatment. Objectives: In this study, we identify Integrin Subunit Alpha 2 (ITGA2) as a potential target in inhibiting pancreatic cancer progression. Materials and Methods: Cell cycle analysis, gene expression level, and cell proliferation assay are implanted in this study as investigational methods. Two-tailed student's t test is used to compare between the studied groups. Results: Cell cycle analysis for the transformed cell lines revealed increasing in G0/G1 phase and entering the cells the cell cycle arrest (quiescence) after knocking down ITGA2 expression. On the other hand, knocking down the ITGA2 effect, the mesenchymal to epithelial transition and the migration possibility of the cell lines by inhibiting the expression of metastatic marker vimentin. Furthermore, ITGA2 can manipulate the tumor microenvironment by downregulating extracellular matrix proteins (ECM-proteins) LAMB3, and LAMC2. Conclusion: ITGA2 downregulation reduces the cell proliferation, induces the cell cycle arrest, and reduce the possibility of metastasis in pancreatic cancer.
{"title":"The Role of Integrin Subunit Alpha 2 (ITGA2) in Pancreatic Cancer Progression","authors":"R. K. Alfardan, W. N. Alismaeel","doi":"10.31146/1682-8658-ecg-218-10-120-124","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-120-124","url":null,"abstract":"Background: Pancreatic cancer is a relatively uncommon type of cancer, although it is often very aggressive and highly metastases to other parts of the body. Investigating a potential gene marker or gene targeted therapy can improve the patient’s early prognosis and/or treatment. Objectives: In this study, we identify Integrin Subunit Alpha 2 (ITGA2) as a potential target in inhibiting pancreatic cancer progression. Materials and Methods: Cell cycle analysis, gene expression level, and cell proliferation assay are implanted in this study as investigational methods. Two-tailed student's t test is used to compare between the studied groups. Results: Cell cycle analysis for the transformed cell lines revealed increasing in G0/G1 phase and entering the cells the cell cycle arrest (quiescence) after knocking down ITGA2 expression. On the other hand, knocking down the ITGA2 effect, the mesenchymal to epithelial transition and the migration possibility of the cell lines by inhibiting the expression of metastatic marker vimentin. Furthermore, ITGA2 can manipulate the tumor microenvironment by downregulating extracellular matrix proteins (ECM-proteins) LAMB3, and LAMC2. Conclusion: ITGA2 downregulation reduces the cell proliferation, induces the cell cycle arrest, and reduce the possibility of metastasis in pancreatic cancer.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"3 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140241306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-15DOI: 10.31146/1682-8658-ecg-218-10-239-241
A. Mironov, A. B. Safonov, A. B. Moiseev, L. N. Tsvetkova, N. A. Mazurina, A. I. Khavkin
{"title":"A. V. Mazurin (1923-2001) On the 100th anniversary of his birth","authors":"A. Mironov, A. B. Safonov, A. B. Moiseev, L. N. Tsvetkova, N. A. Mazurina, A. I. Khavkin","doi":"10.31146/1682-8658-ecg-218-10-239-241","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-239-241","url":null,"abstract":"<jats:p />","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"95 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140237931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：